Emerging clinical evidence suggests that Novera Retatrutide, a combined-action therapy from Novo Nordisk, could offer a significant advance in weight management. Differing from many existing options, Retatrutide affects both the GLP-1 hormone and glucose-dependent insulinotropic polypeptide (GIP), p